• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Recent Advances in the Study of 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine (CAS: 1289048-18-5) in Chemical Biology and Pharmaceutical Research

The compound 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine (CAS: 1289048-18-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its brominated pyridine core and 4-methylpiperidin-1-yl substituent, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, structural optimization, and biological activity, particularly in the context of kinase inhibition and central nervous system (CNS) targeting.

One of the key areas of interest is the role of 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine as a versatile intermediate in medicinal chemistry. Its unique structure allows for further functionalization, making it a valuable scaffold for the development of novel kinase inhibitors. Recent publications have highlighted its utility in the synthesis of compounds targeting protein kinases involved in cancer and inflammatory diseases. For instance, a 2023 study demonstrated its efficacy as a precursor in the development of selective JAK2 inhibitors, which are critical for treating myeloproliferative disorders.

In addition to its applications in kinase inhibition, this compound has also been explored for its potential in CNS drug discovery. The 4-methylpiperidin-1-yl moiety is known to enhance blood-brain barrier (BBB) penetration, a desirable property for drugs targeting neurological conditions. Recent preclinical studies have investigated derivatives of 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine for their ability to modulate neurotransmitter receptors, such as serotonin and dopamine receptors, suggesting potential applications in treating psychiatric and neurodegenerative disorders.

From a synthetic chemistry perspective, advancements in the preparation of 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine have been reported, with a focus on improving yield and purity. Novel catalytic methods, including palladium-catalyzed cross-coupling reactions, have been employed to streamline its production. These methodological improvements are critical for scaling up synthesis and ensuring the compound's availability for further biological evaluation.

Looking ahead, the continued exploration of 3-Bromo-5-(4-methylpiperidin-1-yl)pyridine and its derivatives holds great promise for drug discovery. Future research directions may include further structural optimization to enhance selectivity and potency, as well as in-depth pharmacological profiling to assess its therapeutic potential. Collaborative efforts between academic and industrial researchers will be essential to translate these findings into clinically viable treatments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)